Ocugen Closes $22.5 Million Offering

Rare Daily Staff

Ocugen, which is developing gene therapies for blinding diseases, said it raised $22.5 million through an underwritten registered direct offering of 15 million shares of its common stock at an offering price of $1.50 per share.

RTW Investments led the offering, with additional participation from new and existing investors.

Ocugen said it intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The company anticipates that the net proceeds will extend its cash runway into the fourth quarter of 2026.

Ocugen’s modifier gene therapy platform has the potential to address significant unmet medical needs for large patient populations through its gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies target the underlying disease mechanisms—complex conditions potentially caused by imbalances in multiple gene networks.

Its lead programs are in retinitis pigmentosa and Stargardt disease.